Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9377000 | 0.80 | HPGD (0.50) | HPGDHTTALDH1A1MAPTHSD17B10 | |
| SCHEMBL5406879 | 0.66 | HPGD (0.56) | HPGDHTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6425971 | 0.63 | RPS6KA3 (0.45) | HPGDHTTALDH1A1MAPTHSD17B10 | |
| SCHEMBL7093373 | 0.62 | CYP2C9 (0.50) | HPGDALDH1A1HSD17B10GAAALOX15 | |
| SCHEMBL515533 | 0.62 | CYP3A4 (0.62) | HPGDALDH1A1MAPTHSD17B10ALOX15 | |
| SCHEMBL13322482 | 0.62 | MAPK1 (0.42) | HPGDHTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10083069 | 0.61 | MAPK1 (0.53) | HPGDHTTALDH1A1CDC7DBF4 | |
| SCHEMBL387339 | 0.61 | ALDH1A1 (0.54) | HTTALDH1A1MAPTHSD17B10GAA | |
| SCHEMBL1369682 | 0.60 | SMN1; SMN2 (0.62) | HPGDHTTALDH1A1MAPTGAA | |
| SCHEMBL6708585 | 0.60 | CDK4 (0.52) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| EP-0327284-B1 | Triazolo(1,5-c)pyrimido(1,4) azines as bronchodilators | RIKER LABORATORIES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5166343-A | Chemical intermediates for bronchodilators | RIKER LABORATORIES, INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5089493-A | Triazolo[1,5-C]pyrimido[1,4]azines as bronchodilators | RIKER LABORATORIES, INC. (US) | 1992-02-18 | — | — | US | disclosed |
| US-4981850-A | Triazolo[1,5-c]pyrimido[1,4]azines as bronchodilators | RIKER LABORATORIES, INC. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0327284-A2 | Triazolo(1,5-c)pyrimido(1,4) azines as bronchodilators | RIKER LABORATORIES, INC. (US) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | HPGD 1244/4885HTT 1551/4885ALDH1A1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.